STAT

Trump’s no stranger to misinformation. But with the coronavirus, experts say that’s dangerous

In their remarks on the #coronavirus, President Trump and members of his administration are contradicting one another and even spreading falsehoods. Experts say it’s not just confusing — it’s dangerous.
Source: Illustration: Alex Hogan/STAT; Photos: Getty Images, CDC

Mixed messages and misinformation aren’t out of the ordinary in the Trump administration. But at a time when the U.S. faces a looming threat from a novel virus, public health experts warn that the administration’s mixed messages aren’t just confusing — they’re dangerous.

On Tuesday, a top official from the Centers for Disease Control and Prevention said the agency expects the virus will begin spreading at a community level in the United States and that disruptions to daily life could be “severe.” But President Trump and members of his administration have also said this week that U.S. containment of the virus is “close to airtight” and that the virus is only as deadly as the seasonal flu. Their statements range from false to unproven, and in some cases, underestimate the challenges that public health officials must contend with in responding to the virus.

“It’s really important for the U.S.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Plans For Generic Wegovy, Cough Syrup Warnings, And More
Biocon is developing a generic version of Novo Nordisk's Wegovy and is prepared to conduct a clinical trial next year if needed.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.

Related Books & Audiobooks